Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic and toxinological characterization of the venom from Peruvian Andes Crotalus durissus.

ABSTRACT: The present study performed the proteomic and biological activities of Peruvian Crotalus durissus, an endangered species reported to cause neuro and myotoxic symptoms. Due to the severity of its envenomation and to its geographical location, Peruvian Crotalus durissus is considered of public health importance in Peru. Snakebite treatment depends on rapid administration of appropriate antivenom. In this sense, the recognition of Peruvian Crotalus durissus venom (PCdV) by Brazilian and Peruvian antivenoms was tested. The results of this study increase the scarce knowledge about PCdV composition and demonstrate antivenom recognition of PCdV proteins, indicating a possible efficiency of these antivenoms to treat Peruvian Crotalus durissus accidents

INSTRUMENT(S): Bruker Daltonics instrument model

ORGANISM(S): Crotalus Durissus (ncbitaxon:8731)

SUBMITTER: carolina rego rodrigues

PROVIDER: MSV000088524 | MassIVE | Mon Dec 06 09:42:00 GMT 2021

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein

Project description:Many people experiencing long COVID symptoms, or post-acute sequelae of SARS-CoV-2 infection (PASC), suffer from debilitating neurologic symptoms (Neuro-PASC). Although symptoms of Neuro-PASC are widely documented, it is still unclear whether virus-specific adaptive immunity is affected in these individuals. We report that Neuro-PASC patients exhibit distinct immunological signatures composed of elevated CD4+ T cell responses toward the C-terminal region of SARS-CoV-2 Nucleocapsid protein when examined both functionally and using TCR sequencing. In contrast, Neuro-PASC patients also have diminished activation of CD8+ memory T cells and increased IL-6 production to Nucleocapsid. Elevated plasma immunoregulatory and reduced pro-inflammatory and antiviral response signatures were evident in Neuro-PASC patients compared with COVID convalescent controls without lasting symptoms, correlating with worse neurocognitive dysfunction. These data provide new insight into the impact of virus-specific cellular immunity on the pathogenesis of long COVID and pave the way for the rational design of predictive biomarkers and therapeutic interventions.

2023-05-24 | GSE225942 | GEO

Longitudinal transcriptome profiling of post-treatment Lyme disease syndrome

Project description:Most Lyme disease patients treated with appropriate antibiotics recover rapidly and completely, but a minority of patients develop persistent symptoms correlating with disseminated disease, a greater severity of illness at presentation, and delayed antibiotic therapy. When lingering or recurrent symptoms are associated with a functional decline and persist for greater than 6 months, patients are considered to meet clinical criteria for post-treatment Lyme disease syndrome (PTLDS), although the exact molecular mechanisms underlying this condition remain unknown. We performed longitudinal whole transcriptome sequencing of PTLDS patients' immune cells. No immune mechanism specific to PTLDS were uncovered to date.

2019-02-15 | GSE77929 | GEO

Gene Expression Profiles in Children with Suspected Sepsis in the Emergency Department

Project description:Around 42,000 children suffer from severe sepsis each year in the US alone, resulting in significant morbidity, mortality and billion dollar expenditures in the US healthcare system. Sepsis recognition is a clinical challenge in children. Biomarkers are needed to tailor appropriate antimicrobial therapies and improve risk stratification. The goal of this study was to determine if gene expression profiles from peripheral blood were associated with pathogen type and sepsis severity in children treated for suspected sepsis.

2020-01-01 | GSE119217 | GEO

Xylella fastidiosa 9a5c: gomesin-treated cells vs. control

Project description:In the xylem vessels of susceptible hosts, such as citrus trees or grapevines, Xylella fastidiosa forms biofilm like-colonies that can block water transport, which appears to correlate to disease symptoms. Besides helping host colonization, bacterial biofilms play an important role in resistance against antimicrobial agents, for instance antimicrobial peptides (AMP). Here we show that gomesin, a potent AMP from a Brazilian tarantula spider, modulates X. fastidiosa gene expression profile upon 60 min treatment with a sublethal concentration. Data from DNA microarray hybridizations revealed that among the up-regulated coding sequences (CDS), some are related to biofilm production. In addition, we show that the biofilm formed by gomesin-treated bacteria is thicker than that formed by non-treated cells or cells exposed to streptomycin. We have also observed that treatment of X. fastidiosa with sublethal concentration of gomesin before inoculation in tobacco plants correlates with reduction in CVC symptoms, an effect possibly due to trapping of bacterial cells to fewer xylem vessels given the enhancement in biofilm production. Together, our results suggest that X. fastidiosa can selectively sense a sublethal concentration of gomesin modulating its gene expression to produce a stronger biofilm that may protect itself against the toxic effects of this AMP. Two-condition experiment, control (PW media) vs. gomesin-treated cells. Biological replicates: 5 control, 5 gomesin-treated, independently grown and harvested. Two replicates (left and right side of slide) per array. Total of 10 slides were hibridized, including dye-swap of and two self-self experiments.

2010-05-16 | E-GEOD-17605 | biostudies-arrayexpress

Xylella fastidiosa 9a5c: gomesin-treated cells vs. control

2010-01-06 | GSE17605 | GEO

Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease

Project description:For the clinical treatment of chronic obstructive pulmonary disease (COPD), it is important not only to improve the airflow limitation by bronchodilation but also to suppress emphysema by controlling inflammation. In this study, we have screened for compounds that prevent elastase-induced airspace enlargement in mice from medicines already used clinically. Mepenzolate bromide, a muscarinic antagonist used to treat gastrointestinal disorders was selected. Intratracheal administration or inhalation of mepenzolate bromide decreased the severity of elastase-induced airspace enlargement, alteration of lung mechanics and respiratory dysfunction. While mepenzolate bromide showed bronchodilatory activity, most of other muscarinic antagonists tested did not improve the elastase-induced pulmonary disorders. Mepenzolate bromide suppressed elastase-induced pulmonary inflammatory responses and production of superoxide anions, and reduced the level of cigarette smoke-induced airspace enlargement and alteration of lung mechanics. Based on these results, we propose that this drug is therapeutically effective for COPD as a consequence of both its anti-inflammatory and bronchodilatory activities. In order to understand the mechanism governing mepenzolate-dependent decrease in inflammatory responses and oxidative stress, we performed DNA microarray analysis at the lung of mepenzolate-administered (or control) mice. We then analyzed gene sets that were differently expressed at 25 hours after administration of mepenzolate using Gene Set Enrichment Analysis (GSEA).

2013-11-13 | E-GEOD-50836 | biostudies-arrayexpress

Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease

Project description:Gaucher disease, a recessive inherited metabolic disorder caused by defects in the gene encoding glucosylceramidase (GlcCerase), can be divided into three subtypes according to the appearance of symptoms associated with central nervous system involvement. We now identify a protein, glycoprotein non-metastatic B (GPNMB), that acts as an authentic marker of brain pathology in neurological forms of Gaucher disease. Using three independent techniques, including quantitative global proteomic analysis of cerebrospinal fluid (CSF) in samples from Gaucher disease patients that display neurological symptoms, we demonstrate a correlation between the severity of symptoms and GPNMB levels. Moreover, GPNMB levels in the CSF correlate with disease severity in a mouse model of Gaucher disease. GPNMB was also elevated in brain samples from patients with type 2 and 3 Gaucher disease. Our data suggest that GPNMB can be used as a marker to quantify neuropathology in Gaucher disease patients and as a marker of treatment efficacy once suitable treatments towards the neurological symptoms of Gaucher disease become available.

2016-06-24 | PXD001654 | Pride

Examining Genetic Differences Among People With 21-Hydroxylase Deficiency

Project description:<p>CAH is a genetic steroidogenesis disorder. The most common form, 21OHD, leads to cortisol deficiency and, in turn, an excess of androgen, a hormone that promotes the development and maintenance of male sex characteristics. As a result of this androgen excess, prepubescent males and newborn, prepubescent, and grown females exhibit mature masculine characteristics. The symptoms and severity of 21OHD vary among individuals with the disease and in adults versus children. The reasons for these differences are not yet known. Current therapy for 21OHD consists of administration of glucocorticoids to replace cortisol and suppress excessive pituitary function. With more information about what genes or factors contribute to the severity of 21OHD, researchers may be able to better treat children and adults with the disease. This study will examine participants' DNA to determine what other genes may affect the severity of 21OHD and may make the disease milder in adults than in children</p> <p>This is a 3-day inpatient study. Once eligibility is confirmed through physical exam and blood analysis, eligible participants are admitted to the study site in the morning on the first study day. A blood sample is taken and participants receive one 10-mg pill of hydrocortisone. Heart rates and blood pressures are taken every 4 hours throughout the day. In the morning of Day 2, a blood sample will be obtained and a 24 hour urine collection will begin. On the morning of Day 3, another blood sample is obtained. Participants then receive intravenous cosyntropin, a synthetic form of a hormone that the body makes. About 1 hour after this, participants provide a final blood sample. Participants receive a pill of hydrocortisone prior to the end of the study.</p>

| phs001313 | dbGaP

Trascriptome data in the brain from Propolis treated-Alzheimer's disease model mice

Project description:We showed that Brazilian green propolis attenuated Aβ-induced memory and learning impairment. Comprehensive gene expression analysis demonstrated that Brazilian green propolis treatment suppressed inflammation and immune responses via immune cells such as microglia and astrocytes in the brain. These results indicate the potential of Brazilian green propolis as a promising ingredient for preventing AD-type dementia.

2023-06-09 | GSE234109 | GEO

Gene expression changes associated with trajectories of psychopathology in a longitudinal cohort of children and adolescents

Project description:We aimed to identify blood gene expression patterns associated to psychopathological trajectories retrieved from a large community, focusing on the emergence and remission of general psychiatric symptoms. Hundred and three individuals from the Brazilian High-Risk Cohort Study (BHRCS) for mental disorders were classified in four groups according to Child Behavior Checklist (CBCL) total score at the baseline (w0) and after 3 years (w1): low–high (L–H) (N = 27), high–low (H–L) (N = 12), high–high (H–H) (N = 34) and low–low (L–L) groups (N = 30). Blood gene expression profile was measured using Illumina HT-12 Beadchips, and paired analyses comparing w0 and w1 were performed for each group.

2020-05-28 | E-MTAB-9200 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data